Adverum Biotechnologies (NASDAQ:ADVM) is a clinical-stage gene therapy company focused on delivering novel treatments for ocular and rare diseases. Specializing in leveraging its proprietary adeno-associated virus (AAV) technology to deliver targeted therapies directly to affected areas, the company is dedicated to addressing unmet medical needs. Current projects include advancing a robust pipeline of gene therapy candidates, with a lead focus on treating wet age-related macular degeneration (AMD), a serious eye condition that can lead to blindness. Adverum's objective is to pioneer transformative, one-time treatments that can sustainably improve the lives of patients suffering from ocular and rare diseases without the need for repeated interventions.